lobbying_activities: 2959267

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2959267	9f87c7ae-eaa1-4970-9324-8baee32e8d00	Q1	DAVE KOLBE CONSULTING	401104329	PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION	2023	first_quarter	PHA	S. 113 Prescription Pricing for the People Act of 2023 S. 127 Pharmacy Benefit Manager Transparency Act of 2023 As a result of their impact on the prices charged to the patient or sponsor, many of the contractual and billing practices of the non-manufacturer links in the drug supply chain provide unnecessary barriers to receiving access to needed prescription drugs. Among others, these impact the participants, dependents, beneficiaries and survivors who receive their health benefits from jointly managed, multiemployer health benefit plans. These realities are in direct conflict with the stated policy positions of PILMA. The proposed Senate bills, S. 113 and S. 127 are both steps in the right direction although modifications and additional provisions that would strengthen the legislation.	SENATE	30000		0	0	2023-04-14T10:27:32-04:00